<DOC>
	<DOCNO>NCT02074657</DOCNO>
	<brief_summary>To determine safety profile immunotherapy natural killer cell activate expand ( NKAEs ) salvage chemotherapy child , adolescent young adult relapse refractary acute leukemia</brief_summary>
	<brief_title>`` LANK-2 '' : Activated Expanded NK Cell Immunotherapy Together With Salvage Chemotherapy Children , Adolescents Young Adults With Relapsed Refractary Acute Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Acute Disease</mesh_term>
	<criteria>1 . Patients 0 23 year age diagnosis acute lymphoblastic leukemia , second relapse situation , posttransplant relapse refractary , 2 . Patients 0 23 year age diagnosis acute myeloblastic leukemia , relapse refractary . ( Patient must meet inclusion criterion 1 2 ) 3 . Lansky index &gt; 60 % 4 . Mild ( &lt; 2 ) functional organ alteration ( hepatic , renal , respiratory ) accord National Cancer Institute criterion ( NCI CTCAE v4 ) . 5 . Left ventricular ejection fraction &gt; 39 % 6 . To grant informed consent accordance current legal regulation . 7 . Presence compatible haploidentical donor ( father mother brother ) . 1 . Patients history bad therapeutical compliance 2 . Patients valid psychosocial evaluation 3 . Positive HIV serology</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>23 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Immunotherapy</keyword>
	<keyword>NKAEs</keyword>
	<keyword>Expanded haploidentical natural killer cell</keyword>
	<keyword>Activated natural killer cell</keyword>
</DOC>